

ORIGINAL ARTICLE

## Efficient secretion of a modified E7 protein from human papilloma virus type-16 by *Lactococcus lactis*

D. Quistián-Martínez<sup>1</sup>, J. Villatoro-Hernández<sup>2</sup>, M.J. Loera-Arias<sup>2</sup>, B.R. Rangel-Colmenero<sup>2</sup>, L.M. Zavala-Flores<sup>2</sup>, J. Sepúlveda-Saavedra<sup>2</sup>, S. Guzmán-López<sup>3</sup>, R.E. Elizondo-Omaña<sup>3</sup>, R. Montes-de-Oca-Luna<sup>2</sup> and O. Saucedo-Cárdenas<sup>2,4</sup>

1 Departamento de Bioquímica, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León (UANL), San Nicolás de los Garza, N.L. México

2 Departamento de Histología, Facultad de Medicina, UANL, Monterrey, N.L. México

3 Departamento de Anatomía Humana, Facultad de Medicina, UANL, Monterrey, N.L. México

4 División de Genética, Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social (IMSS), Monterrey, N.L. México

### Keywords

antitumour protection, HPV-16, *Lactococcus lactis*, modified E7, secretion.

### Correspondence

Odila Saucedo-Cárdenas, División de Genética, Centro de Investigación Biomédica del Noreste, IMSS. Col. Independencia, Monterrey, N. L. México 64720.  
E-mail: odilam@hotmail.com

D. Quistián-Martínez and J. Villatoro-Hernández have contributed equally to this work.

Present address: J. Villatoro-Hernandez, Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Kerklaan 30, 9751 NN Haren, NED. Kluyver Centre for Genomics of Industrial Fermentation, PO Box 5057, 2600 GA Delft, The Netherlands.

2010/0493: received 26 March 2010, revised 2 July 2010 and accepted 11 July 2010

doi:10.1111/j.1472-765X.2010.02905.x

### Introduction

More than 99% of cervical cancers are associated with the human papilloma virus (HPV). In these HPV-associated tumours, two viral proteins remain expressed, E6 and E7. The development of vaccines and immunotherapies against cervical tumours targeting these viral oncoproteins has been documented to be effective and highly immunogenic (Roden and Wu 2006; Kim *et al.* 2008). Immunization with E7 has been shown to cause specific therapeutic effects against established E7-expressing tumours in mice

### Abstract

**Aims:** To create and provide a strain of the food-grade bacterium *Lactococcus lactis* able to efficiently secrete a modified form of the E7 protein from the human papilloma virus (HPV) type-16.

**Methods and Results:** We cloned the coding sequence of a modified E7 (E7m) from the HPV-16 in a plasmid regulated by the strong expression promoter p59. Secretion of the E7m was made by the signal peptide of the *usp45* gene. The E7m was detected by Western blot in the cell-free-medium fraction, showing no degradation or aberrant forms.

**Conclusions:** We constructed a strain of *L. lactis* able to secrete efficiently a HPV-16 E7 modified protein with diminished transforming activity.

**Significance and Impact of the Study:** Human papilloma virus infection is associated with more than 99% of cervical cancers. Immunotherapy targeting E7 to treat HPV-associated cervical malignancies has been demonstrated to be highly efficient. However, native E7 maintains transforming activity. We present this new strain of a food-grade bacterium able to efficiently secrete a HPV-16 E7-modified protein with diminished transforming activity. This new strain could be used as a live vaccine to deliver E7 at a mucosal level and generate antitumour immune responses against HPV-associated tumours.

(Kim *et al.* 2007). Even though the use of this viral protein as immunotherapy against cervical cancer was shown to be specific and effective, it possesses an undesired characteristic. This unfavourable condition is that E7 maintains its transforming activity (Shi *et al.* 1999). This inconvenience was overcome by the modification of two repeating Cys-X-X-Cys sequence motifs at the carboxyl terminus of E7 in the CR3 domain containing residues 58–61 and 91–94 with repeating cysteines, which is necessary for the formation of a zinc finger, an important structure that gives stability to the E7 protein. The inability of

this modified E7 to form this particular structure dramatically diminishes its transforming activity in cultures *in vitro* of murine and human cells (McIntyre *et al.* 1993).

It has been demonstrated that this modified E7 is degraded rapidly by the proteasome and that a greater amount of antigenic peptides are being transported to the endoplasmic reticulum and presented to antigen-presented cells (APCs) (Shi *et al.* 1999). Moreover, this modified E7 with altered motifs has a reduced ability to transform a variety of rodent fibroblasts, fails to immortalize human keratinocytes, and exhibits a lower transactivating efficiency (McIntyre *et al.* 1993). Immunization with this modified E7 caused stronger protection immunity against E7-expressing cell lines than the wild-type E7 (Shi *et al.* 1999).

For years, the use of *L. lactis* to produce and deliver heterologous proteins of medical interest has been demonstrated to be efficient and innocuous (Wells and Mercenier 2008). The intranasal immunization with this food-grade bacterium expressing antigens has resulted in the generation of specific protective and therapeutic responses against infectious and chronic diseases (Hanniffy *et al.* 2007; Wells and Mercenier 2008). We have constructed a strain of the lactic acid bacterium (LAB) *L. lactis* able to secrete a modified E7 of the HPV that may be used as a live vaccine against the HPV-16 and tumours associated with this virus.

## Materials and methods

### Bacterial strains and growth conditions

*Escherichia coli* DH5 $\alpha$  was grown aerobically in Luria Bertani broth at 37°C with vigorous agitation. The *L. lactis* strain MG1363 was grown aerobically in M17 broth supplemented with 0.5% glucose (GM17) at 30°C without agitation. Selection of clones was carried out by the addition of 100  $\mu\text{g ml}^{-1}$  of ampicillin for *E. coli* and 75  $\mu\text{g ml}^{-1}$  of erythromycin for *L. lactis*. All constructions were first established in *E. coli* and then transferred to *L. lactis* by electrotransformation using the method previously described (Holo and Nes 1989). Plasmid DNA isolation, DNA manipulation, and PCR were carried out essentially as described (Sambrook *et al.* 1989).

### Protein extraction from *L. lactis*

Cell and cell-free-medium fractions were prepared separately. Samples were processed from 1.35 ml of the culture. Cell pellets were obtained by centrifugation at 21000  $g$  at 4°C for 5 min, and the pellets resuspended in 100  $\mu\text{l}$  of TES-lysis buffer (25% sucrose, 1 mmol  $\text{l}^{-1}$  EDTA, 50 mmol  $\text{l}^{-1}$  Tris·HCl [pH 8.0], lysozyme [10 mg  $\text{ml}^{-1}$ ]

complemented with 1 mmol  $\text{l}^{-1}$  phenylmethylsulfonylfluoride (PMSF), and 10 mmol  $\text{l}^{-1}$  of dithiothreitol). The mixture was incubated at 37°C for one h, and then 50  $\mu\text{l}$  of 20% SDS and one volume of loading buffer were added. The samples were maintained at  $-20^{\circ}\text{C}$  before loading onto the gel.

The cell-free-medium samples were treated with 1 mmol  $\text{l}^{-1}$  of PMSF and 10 mmol  $\text{l}^{-1}$  of dithiothreitol to avoid proteolysis. Proteins were precipitated using 150  $\mu\text{l}$  of 100% trichloroacetic acid (TCA) and incubated on ice for 10 min, then followed by centrifugation at 21000  $g$  at 4°C for 15 min. The pellet was resuspended in 50  $\mu\text{l}$  of 50 mmol  $\text{l}^{-1}$  NaOH and 50  $\mu\text{l}$  of SDS-PAGE loading buffer (100 mmol  $\text{l}^{-1}$  Tris·HCl, [pH 6.8], 200 mmol  $\text{l}^{-1}$  dithiothreitol, 4% SDS, 0.1% bromophenol blue, and 10% glycerol).

### SDS-PAGE and Western blotting

One-fifteenth of the whole cell extracts and one-fifth of the cell-free-medium fractions from 1.35 ml culture were loaded onto 12% acrylamide gels. SDS-PAGE and Western blotting were carried out essentially as described (Sambrook *et al.* 1989). Immunodetection of E7 was carried out by the use of monoclonal anti-E7 (Santa Cruz Biotechnology, Santa Cruz, CA) as a primary antibody and protein-G horseradish peroxidase conjugate (Bio-Rad, Hercules, CA) and the SuperSignal West Pico Chemiluminescent Substrate kit (Thermo Scientific Pierce, Rockford, IL) as recommended by the suppliers.

### Coomassie Blue staining

Twelve per cent SDS-PAGE gels with electrophoresed protein samples were submerged in CBB Buffer (0.1% Coomassie Brilliant Blue R-250, 20% methanol, 0.5% acetic acid) overnight. The gel was incubated in destaining buffer (40% methanol, 7% acetic acid) for 2 h at room temperature with mild agitation.

## Results

### Generation of an expression system to secrete the modified E7 by *L. lactis*

The modified-E7 DNA coding sequence was PCR-amplified from plasmid BC219-E7 (kindly donated by Dr Liang Qiao) using oligos *Sall*-Fw 5-AGTCGACCCATTGCATG GAGATACACCTACATTG-3 and *TER*-Rv 5-ATCAAAA AAAAGCCCGCTCATTAGGCGGGCTATTTATGGTTTC TGAGAACAGA-3. *Sall*-Fw oligo generated a *Sall* restriction site in the E7 amplicon (underlined) at the 5' terminus that allowed the cloning of the E7m sequence

in-frame with the signal peptide of *usp45*, the most secreted protein of *L. lactis* (van Asseldonk *et al.* 1990). The TER-Rv oligo generated a *rho*-independent transcription terminator for clone stability (underlined) and a stop codon (in bold). Amplicons were directly cloned into pGEM-T Easy Vector (Promega, Madison, WI) and then digested with *SalI-SpeI* sequentially. The fragment corresponding to E7m was subcloned in the pVE-5524 vector cut with the same enzymes. This new plasmid (pSEC-E7m) has controlling sequences to allow expression and secretion of E7m under the regulation of the high expression and constitutively active promoter p59 (Fig. 1). The pSEC-E7m was introduced into the *L. lactis* strain MG1363 by electroporation. Clones were selected by the resistance to erythromycin. This newly constructed strain of *L. lactis* was named Ll-pSEC-E7m. All constructs were characterized by endonuclease restriction analysis and PCR and sequenced to verify DNA integrity.

### Secretion of E7m by *L. lactis*

**Detection of E7m by Coomassie blue staining.** To evaluate the ability of the strain Ll-pSEC-E7m to secrete E7m, protein extracts from cell and cell-free-medium fractions were made from cultures of our recombinant strain. For this, we allowed cultures of the Ll-pSEC-E7m to reach an OD<sub>600nm</sub> of one. From each culture, 1.35 ml was centrifuged at 17000 g for five min at 4°C to separate bacteria and the cell-free medium. The cell-free medium was filtered through a 0.22-µm pore-diameter (Milipore, Billerica, MA) filter to remove the remaining bacteria. The total proteins were precipitated with TCA (for more details, see materials and methods). Samples from the cell fractions of *L. lactis* were prepared as well. After electrophoresis, acrylamide gels were stained with Coomassie Blue to visualize total proteins from the cell- and cell-free-medium protein extracts from cultures of *L. lactis*.

Figure 2a shows the electrophoresed *L. lactis* protein samples from the strains transformed with an empty vector (pSEC) and our recombinant strain Ll-pSEC-E7m. Samples from the cell-free medium of our recombinant



**Figure 1** Expression cassette for E7m secretion by *L. lactis*. Coding sequence of E7m was placed under control of the high-expression constitutive p59 promoter (striped bar), the ribosome binding site (RBS) indicated in the empty bar, and the signal peptide of *usp45* from *L. lactis*. The grey bar (Ter) represents a *rho*-independent *trpA* transcription terminator fused just downstream to the E7m gene.

strain revealed the secretion of a distinctive protein band that corresponds to the expected size of the E7m (indicated with asterisk in Fig. 2a). This particular protein band is absent in the cell-free-medium samples from *L. lactis* transformed with the empty vector pSEC (lacking the E7m-coding sequence) and in whole cell-extract samples from both strains. The stain intensity of this secreted protein is close in amount to the major lactococcal secreted protein Usp45 (indicated by a double asterisk in Fig. 2a).


**Detection of E7m by Western blot.** To determine whether the secreted protein band seen in the SDS-PAGE protein gel corresponds to the protein E7, a duplicated gel from Fig. 2a was analysed by immunoblotting using a mouse monoclonal anti-E7 (Santa Cruz). Western blot analysis revealed a single clear band in the sample from the cell-free cultures of our recombinant strain Ll-pSEC-E7m corresponding to the expected size of E7m (Figure 2b). Moreover, no signal was detected in the whole cell fraction of this recombinant strain, meaning that the secretion of E7m was achieved successfully and that no protein remained inside the cell. As expected, no signal was detected in either of the samples from cell-free cultures or cell fractions of *L. lactis* wild-type (data not shown) or in *L. lactis* transformed with an empty vector (pSEC) with no E7m coding sequence (Fig. 2b).

### Discussion

The E7 protein of the HPV has been demonstrated to be a good target to develop both prophylactic and therapeutic tumour vaccines (Roden and Wu 2006; Kim *et al.* 2008). Immunization with this antigen has been demonstrated to cause a specific, cytotoxic immune response against tumours expressing E7. An adverse side effect of this is that E7 maintains its transforming activity, increasing the risk of cellular transformation.

We made a strain of the food-grade bacterium *L. lactis*, a lactic acid bacterium (LAB), able to secrete a modified E7 from the HPV type-16. To address the E7m outside the cell, we made use of the signal peptide from the *usp45* protein, which is the most secreted protein of *L. lactis* (van Asseldonk *et al.* 1993).

Western blot analysis using specific monoclonal antibodies corroborated the highly efficient secretion of E7m by *L. lactis*. Only one strong signal corresponding to E7m was detected in the cell-free-medium sample of the recombinant lactococcus. The absence of signal in the whole-cell extract sample means that the E7m protein was efficiently processed and secreted by this recombinant lactococcus.



**Figure 2** Expression analysis of E7m secretion by recombinant *L. lactis*. The cell fraction (C) and cell-free-medium (M) proteins from cultures of *L. lactis* were electrophoresed by SDS-PAGE and analysed by Coomassie Blue staining (2a) and Western blotting using specific anti-E7 antibodies (2b). An 18-kDa band of the expected size (\*) was detected in the recombinant strain carrying the plasmid pSEC-E7m. W is the molecular mass marker and (\*\*) indicates the native usp45 protein. Only an 18-kDa band corresponding to E7m was detected in the recombinant strain carrying the plasmid pSEC-E7m in samples from the cell-free medium. No signal was detected in the cell fraction of this same strain or in the control strain transformed with the mock vector.

The secreted protein identified as E7 by Western blot corresponds to the Coomassie-Blue-stained protein shown in the SDS-PAGE gels. It is noteworthy to compare the intensity of this E7m band (indicated with an asterisk in Fig. 2a) with that of the usp45, which is the major protein secreted in *L. lactis* (indicated with a double asterisk). In this work, we used the usp45 secretion signal to secrete our E7m. Both the usp45-protein bands, from strains transformed with an empty vector (with no E7m coding DNA sequence) and the recombinant transformed with the vector coding for E7m, were similar in intensity. This outcome indicates how a heterologous protein expressed by *L. lactis* using an endogenous-signal peptide may be secreted in the same manner and undergo the same processing as the native protein from which the signal peptide was used.

Because this strain of *L. lactis* is able to secrete considerable amounts of E7m, it could be used in large-scale bioreactors to produce E7m in large amounts, with several benefits including the favourable quality of this food-grade bacterium that does not produce lipopolysaccharides or any other toxins.

For years, *L. lactis* has been used to express heterologous proteins of medical importance. In 2008, the intranasal immunization with a strain of *L. lactis* expressing the PspA antigen of *Streptococcus pneumoniae* demonstrated the ability to generate a protective immunity in mice challenged with this pathogen (Hanniffy *et al.* 2007). Another strain of *L. lactis* expressing the interleukin 10 is now in Phase I of clinical trials in humans to treat the inflammatory bowel disorder Crohn's disease (Braat *et al.* 2006). Because the use of this micro-organism has been shown to be competent and safe, and more

importantly, to cause specific immune responses against chronic and infectious diseases, we propose the use of this new strain of *L. lactis* able to secrete the E7 of the HPV for the development of a new live vaccine against cervical cancer. Further studies will be necessary to confirm the diminished transforming properties of this modified E7 antigen to cause specific antitumour activity against HPV-associated tumours and infections with this virus associated in more than 90% of cervical cancers.

Actogenix and Mucosis (to our knowledge) are the first two companies offering several vaccines based on *L. lactis* expressing immunomodulators and antigens of viral and bacterial origin to treat pneumonia, mucositis, and influenza. The value of more strains available to make preclinical and clinical trials using *L. lactis* can provide feasible and imminent new biopharmaceuticals that can become commercially available in a short time. This strain, efficiently secreting E7, may be able to determine the therapeutic ability to cause specific immune responses against E7-tumour-bearing organisms, without the transforming activity of E7 (Audouy *et al.* 2007; Steidler *et al.* 2009).

### Acknowledgements

JVH, MJLA, BRRC and LMZF are recipients of a PhD scholarship from CONACyT of Mexico. The authors thank Dr Qiao for donating BC219-E7 plasmid. Thanks to Dr Ellis Glazier for editing this English-language text.

### References

van Asseldonk, M., Rutten, G., Oteman, M., Siezen, R.J., de Vos, W.M. and Simons, G. (1990) Cloning of usp45, a

- gene encoding a secreted protein from *Lactococcus lactis* subsp. *lactis* MG1363. *gene* **95**, 155–160.
- van Asseldonk, M., de Vos, W.M. and Simons, G. (1993) Functional analysis of the *Lactococcus lactis* usp45 secretion signal in the secretion of a homologous proteinase and a heterologous alpha-amylase. *Mol Gen Genet* **240**, 428–434.
- Audouy, S.A., van Selm, S., van Roosmalen, M.L., Post, E., Kanninga, R., Neef, J., Estevão, S., Nieuwenhuis, E.E. *et al.* (2007) Development of lactococcal GEM-based pneumococcal vaccines. *Vaccine* **25**(13), 2497–2506.
- Braat, H., Rottiers, P., Hommes, D.W., Huyghebaert, N., Remaut, E., Remon, J.P., van Deventer, S.J., Neiryck, S. *et al.* (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. *Clin Gastroenterol Hepatol* **4**, 754–759.
- Hanniffy, S.B., Carter, A.T., Hitchin, E. and Wells, J.M. (2007) Mucosal delivery of a pneumococcal vaccine using *Lactococcus lactis* affords protection against respiratory infection. *J Infect Dis* **195**, 185–193.
- Holo, H. and Nes, I.F. (1989) High-Frequency Transformation, by Electroporation, of *Lactococcus lactis* subsp. *cremoris* Grown with Glycine in Osmotically Stabilized Media. *Appl Environ Microbiol* **55**, 3119–3123.
- Kim, D., Hoory, T., Wu, T.C. and Hung, C.F. (2007) Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4 + T cell. *Hum Gene Ther* **18**, 1129–1139.
- Kim, D., Gambhira, R., Karanam, B., Monie, A., Hung, C.F., Roden, R. and Wu, T.C. (2008) Generation and characterization of a preventive and therapeutic HPV DNA vaccine. *vaccine* **26**, 351–360.
- McIntyre, M.C., Frattini, M.G., Grossman, S.R. and Laimins, L.A. (1993) Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. *J Virol* **67**, 3142–3150.
- Roden, R. and Wu, T.C. (2006) How will HPV vaccines affect cervical cancer? *Nat Rev Cancer* **6**, 753–763.
- Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual*, 2nd edn. NY.
- Shi, W., Bu, P., Liu, J., Polack, A., Fisher, S. and Qiao, L. (1999) Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumour activity. *J Virol* **73**, 7877–7881.
- Steidler, L., Rottiers, P. and Coulie, B. (2009) Actobiotics as a novel method for cytokine delivery. *Ann N Y Acad Sci* **1182**, 135–145.
- Wells, J.M. and Mercenier, A. (2008) Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. *Nat Rev Microbiol* **6**, 349–362.